Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche Files IND for Genmab Antibody | Contract Pharma

What are you searching for?

Sign in

Roche Files IND for Genmab Antibody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche has filed an IND with the FDA for a Genmab antibody developed under the companies’ collaboration. Genmab will receive a milestone payment from Roche.

Under the agreement with Roche, Genmab uses its antibody expertise and development capabilities to create human antibodies to a range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. Genmab may also obtain rights to develop products based on disease targets identified by Roche. Genmab stands to receive as much as $100 million plus royalties if all goals are reached.

“This will be the second antibody produced under our collaboration with Roche to enter the clinic and Genmab’s seventh antibody to enter clinical development overall,” said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab. “Our partnership with Roche continues to bear fruit and add value to Genmab’s expanding product pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters